Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OBE022 + atosiban
- Development stage
- Phase 2
- Lead developer
- ObsEva
- Modality
- Small Molecules, Peptides
- Administration
- Oral, Intravenous
01
Overview
**OBE022 + atosiban** is a combination therapy evaluated for the prevention of preterm labor. OBE022 (ebopiprant) is a novel, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist aimed at reducing inflammation and uterine contractions by blocking the action of PGF2α, a key driver of myometrial contractility. Atosiban is a peptide oxytocin and vasopressin receptor antagonist used intravenously as a tocolytic agent to suppress premature labor by inhibiting oxytocin-mediated uterine contractions and reducing prostaglandin release. This combination is being studied as a sequential or simultaneous regimen for women with threatened preterm labor to prolong pregnancy by targeting complementary pathways that control uterine activity[3][1][4].
- Brand names
- Tractocile
- Other names
- TractocileCAP-449CAP449CAP 449CAP-476CAP476CAP 476CAP-581CAP581CAP 581F-314F314F 314ORF 22164ORF22164ORF-22164RW-22164RW22164RW 22164RWJ 22164RWJ22164RWJ-22164
02
Targets
Oxytocin receptorPTGFR (Prostaglandin F2 alpha receptor)AVPR1A (Arginine vasopressin receptor 1A)AVPR2 (Arginine vasopressin V2 receptor)
Beyond the preview
Go deeper on OBE022 + atosiban.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OBE022 + atosiban.